These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3554156)

  • 1. Fluoxetine: a serotonin-specific, second-generation antidepressant.
    Sommi RW; Crismon ML; Bowden CL
    Pharmacotherapy; 1987; 7(1):1-15. PubMed ID: 3554156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
    Benfield P; Heel RC; Lewis SP
    Drugs; 1986 Dec; 32(6):481-508. PubMed ID: 2878798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of new treatments for depression.
    Montgomery SA
    J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):3-6. PubMed ID: 3882678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open trial of fluoxetine in the treatment of panic attacks.
    Gorman JM; Liebowitz MR; Fyer AJ; Goetz D; Campeas RB; Fyer MR; Davies SO; Klein DF
    J Clin Psychopharmacol; 1987 Oct; 7(5):329-32. PubMed ID: 3500189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of antidepressants.
    Kasper S; Fuger J; Möller HJ
    Drugs; 1992; 43 Suppl 2():11-22; discussion 22-3. PubMed ID: 1378369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent studies on selective serotonergic antidepressants: trazodone, fluoxetine, and fluvoxamine.
    Schatzberg AF; Dessain E; O'Neil P; Katz DL; Cole JO
    J Clin Psychopharmacol; 1987 Dec; 7(6 Suppl):44S-49S. PubMed ID: 3123528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
    Dechant KL; Clissold SP
    Drugs; 1991 Feb; 41(2):225-53. PubMed ID: 1709852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance.
    Leonard BE
    Drugs; 1992; 43 Suppl 2():3-9; discussion 9-10. PubMed ID: 1378371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obsessive compulsive disorder, depression, and fluoxetine.
    Hollander E; Mullen L; DeCaria CM; Skodol A; Schneier FR; Liebowitz MR; Klein DF
    J Clin Psychiatry; 1991 Oct; 52(10):418-22. PubMed ID: 1938978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action.
    Marek GJ; McDougle CJ; Price LH; Seiden LS
    Psychopharmacology (Berl); 1992; 109(1-2):2-11. PubMed ID: 1365657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression.
    Byerley WF; Reimherr FW; Wood DR; Grosser BI
    J Clin Psychopharmacol; 1988 Apr; 8(2):112-5. PubMed ID: 3286684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression.
    Davis R; Wilde MI
    CNS Drugs; 1996 May; 5(5):389-402. PubMed ID: 26071050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
    Etain B; Bonnet-Perrin E
    Encephale; 2001; 27(3):280-9. PubMed ID: 11488259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
    Koran LM; Cain JW; Dominguez RA; Rush AJ; Thiemann S
    Am J Psychiatry; 1996 Nov; 153(11):1450-4. PubMed ID: 8890679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test.
    Page ME; Detke MJ; Dalvi A; Kirby LG; Lucki I
    Psychopharmacology (Berl); 1999 Nov; 147(2):162-7. PubMed ID: 10591883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Metabolites of Antidepressants in the Treatment of Depression.
    Rudorfer MV; Potter WZ
    CNS Drugs; 1997 Apr; 7(4):273-312. PubMed ID: 27520753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression.
    Fawcett J; Barkin RL
    J Affect Disord; 1998 Dec; 51(3):267-85. PubMed ID: 10333982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoxetine: a spectrum of clinical applications and postulates of underlying mechanisms.
    Messiha FS
    Neurosci Biobehav Rev; 1993; 17(4):385-96. PubMed ID: 8309648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A test for using meta-analysis to evaluate antidepressive effects of fluoxetine].
    Jarema M
    Psychiatr Pol; 1996; 30(4):569-81. PubMed ID: 8975258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.